NEW DELHI (IDN) – Failures of the patent system to meet the public health priorities demand a new approach in research and development (R&D) financing and incentive to pharmaceutical innovations. An R&D model delinking the cost of R&D from the price of the product is the way forward.
As we eagerly await a vaccine for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), we are reminded of 2003 SARS and 2012 Middle East respiratory syndrome (MERS).
Image: Image: Collage of pictures about biomedical research. Source: Delhi Posr
